Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Short-term Investments (2021 - 2023)

HCW Biologics (HCWB) has disclosed Short-term Investments for 3 consecutive years, with $10.0 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Short-term Investments fell 41.39% year-over-year to $10.0 million, compared with a TTM value of $10.0 million through Jun 2023, down 41.39%, and an annual FY2022 reading of $9.7 million, down 61.03% over the prior year.
  • Short-term Investments was $10.0 million for Q2 2023 at HCW Biologics, up from $9.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $25.0 million in Q3 2021 and bottomed at $9.7 million in Q4 2022.
  • Average Short-term Investments over 3 years is $16.2 million, with a median of $17.0 million recorded in 2022.
  • The sharpest move saw Short-term Investments crashed 61.03% in 2022, then crashed 41.39% in 2023.
  • Year by year, Short-term Investments stood at $25.0 million in 2021, then plummeted by 61.03% to $9.7 million in 2022, then grew by 2.3% to $10.0 million in 2023.
  • Business Quant data shows Short-term Investments for HCWB at $10.0 million in Q2 2023, $9.8 million in Q1 2023, and $9.7 million in Q4 2022.